- Home
- HFRO vs AVIR Comparison
HFRO vs AVIR Comparison
Compare HFRO & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HFRO | AVIR |
|---|---|---|
| Founded | 2000 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 393.9M | 434.5M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | HFRO | AVIR |
|---|---|---|
| Price | $7.46 | $4.88 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 206.0K | ★ 330.7K |
| Earning Date | 01-01-0001 | 05-11-2026 |
| Dividend Yield | ★ 8.87% | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.03 | $2.78 |
| 52 Week High | $7.60 | $6.45 |
Technical Indicators
Market Signals| Indicator | HFRO | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 69.04 | 60.79 |
| Support Level | $6.23 | $4.14 |
| Resistance Level | N/A | $6.37 |
| Average True Range (ATR) | 0.19 | 0.21 |
| MACD | -0.00 | 0.08 |
| Stochastic Oscillator | 84.13 | 82.72 |
Price Performance
Historical ComparisonAbout HFRO Highland Opportunities and Income Fund of Beneficial Interest
Highland Opportunities and Income Fund is a non-diversified, closed-end management investment company. Its investment objective is to Income Fund seeks growth of capital along with income. It focuses on making investments in real estate securities, including Reits, secured and unsecured fixed-rate loans and corporate bonds, mezzanine securities, structured products, convertible and preferred securities and equities (public and private), and floating rate securities.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.